SELLAS Life Sciences Group, Inc. develops novel cancer therapeutics as a late-stage clinical biopharmaceutical company. News about SLS centers on its acute myeloid leukemia programs, including galinpepimut-S (GPS), a WT1-directed peptide immunotherapy evaluated in the REGAL Phase 3 trial, and SLS009 (tambiciclib), a selective CDK9 inhibitor studied in AML settings.
Recurring updates include clinical and preclinical data presentations, trial progress, regulatory and corporate updates, financial results, cash-position disclosures, warrant exercises, and other capital-structure developments tied to funding its oncology pipeline.
SELLAS Life Sciences Group (NASDAQ: SLS) announced significant advancements in Q1 2022, including the in-licensing of GFH009, a selective CDK9 inhibitor from GenFleet Therapeutics, which aims to enhance their cancer therapy pipeline. The company closed a public offering raising $25 million for its development projects, including the GPS treatment for acute myeloid leukemia and other cancers. Key organizational changes include the appointment of Robert Francomano as Chief Commercial Officer. Enrollment in the Phase 1/2 GPS study with KEYTRUDA is completed, and an IND for GPS in China is approved.
SELLAS Life Sciences Group (NASDAQ: SLS) announced a public offering of 4,629,630 shares of its common stock and accompanying warrants at a price of $5.40 per share. The offering is expected to generate gross proceeds of $25 million before deducting costs. The securities will be sold by the company and the offering is set to close on April 5, 2022, subject to customary conditions. SVB Leerink and Cantor are the joint book-running managers for this offering. The securities are part of a shelf registration statement previously filed with the SEC.
SELLAS Life Sciences Group (Nasdaq: SLS) has initiated an underwritten public offering of its common stock and associated warrants, with all securities sold by the company. SVB Leerink and Cantor are the joint book-running managers for this offering, which is subject to market conditions. The offering will be conducted under a previously filed shelf registration statement. SELLAS is focused on developing novel cancer therapies, notably GPS and GFH009, potentially addressing various malignancies. The completion details depend on market and closing condition satisfaction.
SELLAS Life Sciences Group has entered a license agreement with GenFleet Therapeutics for worldwide rights to develop GFH009, a selective CDK9 inhibitor, outside Greater China. GFH009 is currently in Phase 1 trials in the U.S. and China, showing promising early results and lower toxicity compared to older versions. SELLAS plans to initiate multiple Phase 2 trials in 2023 for hematological malignancies and pediatric soft tissue sarcomas. The financial terms include an initial $10 million payment and potential milestone payments totaling up to $140 million.
SELLAS Life Sciences Group has appointed Robert Francomano as Chief Commercial Officer, effective immediately. With over 25 years of experience in the biopharmaceutical sector, Francomano previously led Stemline Therapeutics through its transition to full commercialization. His expertise is expected to significantly contribute to SELLAS’s pipeline, particularly with its lead candidate, galinpepimut-S (GPS), which targets various tumor types. CEO Angelos Stergiou expressed confidence in Francomano’s capabilities, hoping to advance the company's mission in cancer therapies.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) announced on February 28, 2022, that the United States District Court for the District of New Jersey approved a $1.6 million settlement related to litigation involving its predecessor, Galena Biopharma. The settlement, fully covered by insurance, resolves all legacy legal claims. CEO Angelos M. Stergiou expressed satisfaction with the modest settlement, emphasizing the company's focus on developing innovative cancer immunotherapies. SELLAS's lead candidate, galinpepimut-S, targets the WT1 protein in various tumors.
SELLAS Life Sciences Group (NASDAQ: SLS) has completed enrollment in a Phase 1/2 clinical trial for its lead asset, galinpepimut-S (GPS), in combination with Merck’s KEYTRUDA® for advanced ovarian cancer. The trial aims to assess safety and efficacy in 17 patients, with interim data expected by mid-2022 and final results by the end of 2022. This milestone reflects SELLAS's commitment to improving treatment options for difficult-to-treat patients, despite challenges posed by COVID-19.
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) has had its IND application accepted by China’s NMPA to initiate a Phase I trial of 3D189 (GPS) for hematological malignancies, expected to start in mid-2022. This milestone will trigger a payment to SELLAS, with additional payments linked to further trials. GPS has shown encouraging results in prior studies and aims to improve outcomes for cancer patients globally. Collaboration with 3D Medicines may also extend to ongoing Phase III trials in AML, enhancing their combined treatment options.
SELLAS Life Sciences Group (NASDAQ: SLS) has announced the promotion of John T. Burns to Senior Vice President, Finance, and Chief Accounting Officer. Burns, who joined SELLAS in 2013, has played a vital role in the company’s financial strategy and execution. His promotion reflects his contributions to the company’s growth, particularly in advancing its clinical programs for cancer immunotherapies. SELLAS is developing innovative treatments, including galinpepimut-S and nelipepimut-S, targeting various cancer types.
SELLAS Life Sciences Group (NASDAQ: SLS) announced the final approval on November 19, 2021, by the United States District Court for the District of New Jersey regarding the settlement of claims related to its predecessor, Galena Biopharma, Inc.. This settlement resolves derivative actions Keller v. Ashton and Johnson v. Schwartz and mandates the adoption of new policies for future commercialization of clinical candidates. The company's insurer will cover attorney's fees up to $270,000. SELLAS focuses on developing cancer immunotherapies, with its lead product candidate, galinpepimut-S (GPS).